课题基金 / 基金详情

TEMOZOLOMIDE & BCNU FOR ANAPLASTIC GLIOMAS

TEMOZOLOMIDE & BCNU FOR ANAPLASTIC GLIOMAS
替莫唑胺
批准号：
6263693
负责人：
HARRY S GREENBERG
金额：
$0.02万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6263693
关键词：
astrocytoma carmustine clinical research combination chemotherapy glioma human subject human therapy evaluation neoplasm /cancer chemotherapy temozolomide

项目摘要

项目成果

HARRY S GREENBERG的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
A phase II multicenter North American Brain Tumor Board Consortium trial to treat malignant astrocytomas with the combination of IV BCNU and oral temozolomide. The mechanism of denovo drug-resistance for these drugs is high levels of the enzyme O 6 alkylguanine transferase. BCNU will be used to deplete this enzyme with the theory that temozolomide will be more effective with lower cellular levels of the enzyme. There will be two patient groups studied 1.) recurrent glioblastoma after primary treatment failure (surgery, radiation and chemotherapy) and 2.) anaplastic gliomas and mixed anaplastic gliomas following surgery without prior radiation therapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
MARIMASTAT IN PATIENTS W/ GLIOBLASTOMA MULTIFORME OF GLIOSARCOMA
MARIMASTAT IN PATIENTS W/ GLIOBLASTOMA MULTIFORME OF GLIOSARCOMA
TEMOZOLOMIDE & BCNU FOR ANAPLASTIC GLIOMAS
MARIMASTAT IN PATIENTS W/ GLIOBLASTOMA MULTIFORME OF GLIOSARCOMA
海外基金